Ventures Iii, L.P.5 Am Co I... Net Worth

The estimated Net Worth of Ventures Iii, L.P.5 Am Co I... is at least $8.01 Million dollars as of 28 March 2019. Ventures I owns over 361,129 units of Arvinas Inc stock worth over $2,894,383 and over the last 6 years Ventures sold ARVN stock worth over $5,113,587.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ventures I ARVN stock SEC Form 4 insiders trading

Ventures has made over 1 trades of the Arvinas Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Ventures sold 361,129 units of ARVN stock worth $5,113,587 on 28 March 2019.

The largest trade Ventures's ever made was selling 361,129 units of Arvinas Inc stock on 28 March 2019 worth over $5,113,587. On average, Ventures trades about 180,565 units every 0 days since 2018. As of 28 March 2019 Ventures still owns at least 116,287 units of Arvinas Inc stock.

You can see the complete history of Ventures I stock trades at the bottom of the page.

Insiders trading at Arvinas Inc

Over the last 6 years, insiders at Arvinas Inc have traded over $123,187,141 worth of Arvinas Inc stock and bought 3,567,290 units worth $69,124,444 . The most active insiders traders include Capital Management, L.P.Ra ..., Liam Ratcliffe, and Kush Parmar. On average, Arvinas Inc executives and independent directors trade stock every 22 days with the average trade being worth of $1,884,820. The most recent stock trade was executed by John G Houston on 23 February 2024, trading 5,196 units of ARVN stock currently worth $244,472.

What does Arvinas Inc do?

arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.

Complete history of Ventures I stock trades at Arvinas Inc

Arvinas Inc executives and stock owners

Arvinas Inc executives and other stock owners filed with the SEC include:

• John Houston,
  President, Chief Executive Officer, Director
• Sean Cassidy,
  Chief Financial Officer
• Ian Taylor,
  Chief Scientific Officer
• Ronald Peck,
  Chief Medical Officer
• Dr. John G. Houston Ph.D.,
  CEO, Pres & Director
• Dr. Ronald A. Peck,
  Chief Medical Officer
• Dr. Ian Taylor Ph.D.,
  Chief Scientific Officer
• Sean A. Cassidy CPA, M.B.A., CPA,
  CFO & Treasurer
• Laurie Smaldone Alsup,
  Independent Director
• Leslie Norwalk,
  Independent Director
• Timothy Shannon,
  Independent Chairman of the Board
• Bradley Margus,
  Independent Director
• Briggs Morrison,
  Independent Director
• Liam Ratcliffe,
  Independent Director
• Edward Kennedy,
  Independent Director
• Wendy Dixon,
  Director
• Linda Bain,
  Director
• Steve Weiss,
  VP of HR
• Dr. Randy Teel Ph.D.,
  Sr. VP of Corp. & Bus. Devel.
• Dr. Robert Kleinfield,
  Chief Devel. Officer
• Matthew Batters J.D.,
  Gen. Counsel
• Jeff Boyle,
  VP of Investor Relations
• Dr. Craig M. Crews,
  Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
• Ventures Iii, L.P.5 Am Part...,
  
• David K Loomis,
  Chief Accounting Officer
• Sunil Agarwal,
  Director
• Ix L.P.Canaan Partners Ix L...,
  
• Capital Management, L.P.Ra ...,
  
• Jakob Loven,
  Director
• Andrew Crew,
  See Remarks
• Ventures Iii, L.P.5 Am Co I...,
  
• James E Deerfield Mgmt L.P....,
  
• Craig Martin Crews,
  10% owner
• Kush Parmar,
  Director
• Angela M Cacace,
  Chief Scientific Officer
• John D Young,
  Director
• Everett Cunningham,
  Director
• Noah Berkowitz,
  Chief Medical Officer
• Randy Teel,
  Int. Chief Financial Officer